

GLOBAL BULK DRUGS



Industry Insight

GLOBAL BULK DRUGS



Cygnus

Business Consulting & Research

Knowledge Partner for Profitable Growth

INDUSTRY INSIGHT: GLOBAL BULK DRUGS

The global bulk drugs market, worth an estimated US\$77.33 billion in 2005, grew at a compounded annual growth rate (CAGR) of 9.2% in the last five years. The branded prescription drugs accounted for nearly 86% of the bulk drug consumption in 2005. Of late, the generic prescription drugs segment has emerged as a promising market for bulk drugs. The bulk drug industry is highly-fragmented, with a large number of small players. The bulk drug producers can be classified into three categories:

- Contract manufacturers
- Niche bulk drug manufacturers
- Commodity bulk drug manufacturers

The contract manufacturing of over-the-counter and nutritional products is the largest and fastest growing segment.

SCOPE OF THE REPORT –

The report takes the global bulk drug market in perspective and then the various sub segments. It gives the market overview of Global Pharma and then global bulk drugs. It focuses on the following points –

- The category wise analysis - its growth drivers, key issues and future outlook
- Top 10 bulk drugs in the world, The high potency bulk drugs market
- The regional opportunities in API's
- The growth drivers and issues & challenges
- The major players
- The regulatory issues - cGMP's in USA, Europe, Japan & India
- Drug master files & Drug regulation in China
- The impact of mergers & acquisitions among fine chemicals companies
- Critical success factors
- The vertical integration between generic companies and the research based pharmaceutical companies
- Future outlook

COMPANIES COVERED IN THE REPORT –


This report provides the profiles of 15 major players in the world. Each profile covers business and financial profile, key strategies and outlook. The companies covered are –

Merck KGaA, Teva Pharmaceutical industries, Sandoz, Pliva, Watson Pharmaceuticals, Hexal Ag, Mylan Laboratories Inc, Andrex Corporation, Ratiopharm, Ranbaxy Laboratories, Stada Pharmaceuticals, Actavis, Dr. Reddy's Laboratories Limited and Aurobindo Pharma

FOR WHOM –

- Bulk Drug companies
- Contract manufacturing companies
- Pharmaceutical companies
- Consultants
- Industry & Trade Associations

To place order, post your request to mktg@cygnusindia.com or fax at 91 – 40 – 23430201.



The report includes Executive Summary, Highlights, Market Overview of global P h a r m a a n d Bulk drugs, Growth drivers, Issues and Challenges, Regulatory Issues, Major Players, Critical Success Factors and Future outlook.

No of Pages : 98
List of Tables : 9
List of Charts : 8

Cygnus

Business Consulting & Research
Knowledge Partner For Profitable Growth

Contact us for more details-

Corporate Office: 4th & 5th Floors, Astral Heights, Road No. 1, Banjara Hills, Hyderabad-500034, India,
Tel: +91-40-23430203-05, Fax: +91-40-23430201, E-mail: info@cygnusindia.com; Website: www.cygnusindia.com
Branches: ♦ **Ahmedabad:** 079-26404728/29/30/31 ♦ **Bangalore:** 080-41311229 ♦ **Chennai:** 044-42122168, 42122819
♦ **Hyderabad:** 040-23430209 ♦ **Kolkata:** 033-22890642/43 ♦ **Mumbai:** 022-22870612/14 ♦ **New Delhi:** 011-41520651/52

CONTENTS

1. EXECUTIVE SUMMARY.....	8
2. HIGHLIGHTS	11
3. MARKET OVERVIEW	14
3.1 Global pharmaceutical market	14
3.1.1 Major markets.....	15
3.1.2 Leading therapeutic classes	16
3.1.3 Leading drugs	16
3.2. Global bulk drug market.....	17
3.2.1 Market size	18
3.2.2 Industry structure.....	19
3.2.3 Major segments	21
3.2.4 Top 10 Bulk Drugs –Therapeutic Class-wise.....	22
3.2.5 Major bulk drugs	22
3.2.6 Major markets.....	25
3.2.7 Industry trends	26
4. GROWTH DRIVERS	29
4.1 Growth in the biotechnology sector.....	29
4.2 High growth of generics.....	30
4.3 Growth in CIS countries	31
4.4 A large number of additions to OTC segment.....	32
4.5 New regulation will boost growth of API's.....	32
4.6 New drug developments	34
4.7 Overall pharmaceutical growth	34
5. ISSUES AND CHALLENGES	36
5.1 Overcapacity.....	36
5.2 Competition on the cost front	36
5.3 Undifferentiated capabilities	37
5.4 Backward Integration of Research-based companies	38

5.5 Coping with changing disease profile.....	38
5.6 Varying regulatory requirements lead to additional costs.....	38
6. REGULATORY ISSUES	39
6.1 Intellectual property rights.....	39
6.1.1 General Agreement on Tariffs and Trade, (GATT).....	39
6.1.2 Trade Related Aspects of Intellectual Property Rights (TRIPS)	40
6.1.3 The Paris Convention (PCPIP).....	42
6.1.4 The Patent Co-operation Treaty (PCT)	43
6.2 Prolonging Patent Protection.....	45
6.2.1 GATT & TRIPS	45
6.2.2 The Waxman Hatch Act.....	45
6.3 Current Good Manufacturing Practices (cGMP).....	47
6.3.1 USA.....	47
6.3.2 Europe.....	48
6.3.3 Japan.....	49
6.3.4 India	49
6.4 Drug Master Files.....	49
6.4.1 USA.....	50
6.4.2 Europe.....	51
6.4.3 Japan.....	52
6.5 Drug regulation in China.....	53
7. MAJOR PLAYERS	54
7.1. Merck KGaA.....	54
7.1.1 Business profile	54
7.1.2 Financial profile.....	56
7.1.3 Key strategy	56
7.1.4 Outlook	56
7.2 Teva Pharmaceutical Industries.....	57
7.2.1 Business profile	57
7.2.2 Financial profile.....	58
7.2.3 Key strategies.....	59
7.2.4 Outlook	59
7.3. Sandoz.....	61
7.3.1 Business profile	61
7.3.2 Financial profile.....	62
7.3.3 Key strategy	62
7.3.4 Outlook	63
7.4. Pliva.....	63
7.4.1 Business profile	63
7.4.2 Financial profile.....	64
7.4.3 Key strategy	64

7.4.4 Outlook	65
7.5. Watson Pharmaceuticals	65
7.5.1 Business profile	65
7.5.2 Financial profile	66
7.5.3 Key strategy	67
7.5.4 Outlook	67
7.6. Barr Pharmaceuticals Inc.	68
7.6.1 Business profile	68
7.6.2 Financial profile	69
7.6.3 Key strategy	69
7.6.4 Outlook	70
7.7. Hexal Ag	70
7.7.1 Business profile	70
7.7.2 Key strategy	71
7.7.3 Outlook	71
7.8. Mylan Laboratories Inc.	71
7.8.1 Business profile	71
7.8.2 Financial Profile	73
7.8.3 Key strategy	73
7.8.4 Outlook	73
7.9. Andrx Corporation	73
7.9.1 Business profile	73
7.9.2 Financial profile	75
7.9.3 Key strategy	75
7.9.4 Outlook	75
7.10. Ratiopharm	76
7.10.1 Business profile	76
7.10.2 Key strategy	77
7.10.3 Outlook	77
7.11. Ranbaxy Laboratories	78
7.11.1 Business profile	78
7.11.2 Financial profile	80
7.11.3 Key strategy	80
7.11.4 Outlook	80
7.12. Stada Pharmaceuticals	81
7.12.1 Business profile	81
7.12.2 Financial profile	82
7.12.3 Key strategy	83
7.12.4 Outlook	83
7.13. Actavis	84
7.13.1 Business profile	84
7.12.2 Financial profile	85
7.13.2 Key strategy	85

7.13.3 Outlook	86
7.14. Dr. Reddy's Laboratories Limited	86
7.14.1 Business profile	86
7.14.2 Financial profile	87
7.14.3 Key strategy	88
7.14.4 Outlook	88
7.15. Aurobindo Pharma Ltd	89
7.15.1 Business profile	89
7.15.2 Financial profile	91
7.15.3 Key strategy	91
7.15.4 Outlook	91
8. CRITICAL SUCCESS FACTORS	93
8.1. Low-cost manufacturing skills	93
8.2. Striking strategic alliances	94
8.3. Growing experience with GMP compliance	94
8.4. Complex synthesis capabilities	94
8.5. Targeting right opportunities at right time	95
9. FUTURE OUTLOOK	96

LIST OF ABBREVIATIONS

ANDA – Abbreviated New Drug Application
API – Active Pharmaceutical Ingredient
ARIPO – African Regional Industrial Property Organization
BPC – Bulk Pharmaceutical Chemical
CAGR – Compounded Annual Growth Rate
CEE – Central and Eastern Europe
cGMP – Current Good Manufacturing Practice
CIS – Commonwealth of Independent States
CMO – Contract Manufacturing Organization
CoS – Certificate of Suitability
DMF – Drug Master File
EAPO – Eurasian Patent Office
EPO – European Patent Office
EU – European Union
FDA – Food and Drug Administration
GATT – General Agreement on Tariffs and Trade
HPAPI - High-Potency Active Pharmaceutical Ingredients
ICH – International Conference on Harmonization
IP – Intellectual Property
ISA – International Searching Authority
MHLW - Ministry of Health & Labour Welfare
NDA – New Drug Application
AIPO – African Intellectual Property Organization
OTC – Over-the-Counter
PCPIP – The Paris Convention for the Protection of Industrial Property
PCT – The Patent Co-operation Treaty
PMNC – Pharmaceutical Multinational Corporation
TRIPS – Trade Related Aspects of Intellectual Property Rights
WHO – World Health Organization
WIPO – World Intellectual Property Organization
WTO – World Trade Organization

LIST OF CHARTS

- Chart 1: Global Pharmaceutical Market (2001-2005)
- Chart 2: Global Bulk Drug Market (2001-06)
- Chart 3: Bulk Drug Volume (2001-06)
- Chart 4: Market Share by Different Segments
- Chart 5: Share of Drug Approvals in USA (2001-2005)
- Chart 6: Patent expiries by value (2006-2010)
- Chart 7: Number of new drugs & ANDA approval (2001-2005)
- Chart 8: Global Pharmaceutical Market (2001-2005)

LIST OF TABLES

- Table 1: World Audited Pharmaceutical Sales by Region, 2005
- Table 2: Leading Therapeutic Classes, 2005
- Table 3: Leading Drugs, 2005
- Table 4: Global Bulk Drug Market (US\$ billion)
- Table 5: Top Ten Bulk Drugs –Therapeutic Class-wise, 2005
- Table 6: Major Bulk Drug Products
- Table 7: Global Bulk Drug Sales by Region, 2005
- Table 8: Worldwide Revenue of Contract Manufacturing, 2003-09 (US\$ billion)
- Table 9: India overtakes Italy in bulk drug production